Many drugs in development tend to be aimed at incremental improvements for patients. In which case it’s definitely a major marketing exercise. Trying to dislodge the current market leaders.
Fortunately IMU are bring a whole new field of therapy into play. It’s also cheap and efficient to deliver, as opposed to so many very effective and promising cellular therapies.
As LC has recently stated , recruitment for Vaccinia has been quick and easy. They have trial volunteers lined up around the block. That tells us , this product will sell itself if the trial results are good. Very few if any side affects is enough to sell the product!.
At this stage it’s looking like a ‘cure’ as opposed to a small life extension that comes at a high price both financially and from a quality of life perspective.
IMU Price at posting:
13.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)